The AVANOVA study: niraparib and bevacizumab for ovarian cancer

Combination Therapy With Niraparib and Bevacizumab for Ovarian CancerПодробнее

Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian CancerПодробнее

Combination therapy to treat ovarian cancer: promising results from the ANANOVA trialПодробнее

Dr. Mirza on Safety Profile of Niraparib/Bevacizumab in Recurrent Ovarian CancerПодробнее

Treating Ovarian Cancer With Niraparib: The NOVA TrialПодробнее

Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian CancerПодробнее

Dr. Arend on Niraparib With Bevacizumab in Ovarian CancerПодробнее

The PAOLA-1 study: olaparib and bevacizumab for ovarian cancerПодробнее

Dr. Mirza on the Rationale for the AVANOVA Trial in Recurrent Ovarian CancerПодробнее

Adjuvant Chemotherapy + Bevacizumab for Ovarian CancerПодробнее

Bevacizumab in Recurrent Ovarian CancerПодробнее

When to Add Bevacizumab for Recurrent Ovarian CancerПодробнее

Rationalizing Use of Pembrolizumab/Bevacizumab in Recurrent Ovarian CancerПодробнее

Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian CancerПодробнее

Bevacizumab in Ovarian CancerПодробнее

Ovarian Cancer: Maintenance Following Frontline BevacizumabПодробнее

PARP + Maintenance Bevacizumab in Ovarian CancerПодробнее

GOG-0218: which patients with ovarian cancer experience highest benefit from 1L bevacizumab?Подробнее

Ovarian Cancer Subtypes May Predict Response to BevacizumabПодробнее